Global Biologics Contract Manufacturing Market Outlook, InDepth Analysis & Forecast to 2032生物製剤受託製造の世界市場 2026-2032年 The global Biologics Contract Manufacturing market is projected to grow from US$ 89453 million in 2025 to US$ 173452 million by 2032, at a CAGR of 9.9% (2026-2032), driven by critical product segme... もっと見る
図表リストList of TablesTable 1. Global Biologics Contract Manufacturing Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Table 2. Global Biologics Contract Manufacturing Market Size Growth Rate by Manufacturing Service Type 按, 2021 vs 2025 vs 2032 (US$ Million) Table 3. Global Biologics Contract Manufacturing Market Size Growth Rate by Development and Commercialization Stage, 2021 vs 2025 vs 2032 (US$ Million) Table 4. Global Biologics Contract Manufacturing Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Table 5. Global Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 6. Global Biologics Contract Manufacturing Revenue by Region (US$ Million), 2021-2026 Table 7. Global Biologics Contract Manufacturing Revenue by Region (US$ Million), 2027-2032 Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 9. Global Biologics Contract Manufacturing Revenue by Players (US$ Million), 2021-2026 Table 10. Global Biologics Contract Manufacturing Revenue-Based Market Share by Players (2021-2026) Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue) Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Biologics Contract Manufacturing Revenue, 2025 Table 13. Global Biologics Contract Manufacturing Average Gross Margin (%) by Player (2021 vs 2025) Table 14. Global Biologics Contract Manufacturing Companies Headquarters Table 15. Global Biologics Contract Manufacturing Market Concentration Ratio (CR5) Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment Table 18. Global Biologics Contract Manufacturing Revenue by Type (US$ Million), 2021-2026 Table 19. Global Biologics Contract Manufacturing Revenue by Type (US$ Million), 2027-2032 Table 20. Global Biologics Contract Manufacturing Revenue by Manufacturing Service Type 按 (US$ Million), 2021-2026 Table 21. Global Biologics Contract Manufacturing Revenue by Manufacturing Service Type 按 (US$ Million), 2027-2032 Table 22. Global Biologics Contract Manufacturing Revenue by Development and Commercialization Stage (US$ Million), 2021-2026 Table 23. Global Biologics Contract Manufacturing Revenue by Development and Commercialization Stage (US$ Million), 2027-2032 Table 24. Key Product Attributes and Differentiation Table 25. Global Biologics Contract Manufacturing Revenue by Application (US$ Million), 2021-2026 Table 26. Global Biologics Contract Manufacturing Revenue by Application (US$ Million), 2027-2032 Table 27. Biologics Contract Manufacturing High-Growth Sectors Demand CAGR (2026-2032) Table 28. Top Customers by Region Table 29. Top Customers by Application Table 30. North America Biologics Contract Manufacturing Growth Accelerators and Market Barriers Table 31. North America Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 32. Europe Biologics Contract Manufacturing Growth Accelerators and Market Barriers Table 33. Europe Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million) Table 34. Asia-Pacific Biologics Contract Manufacturing Growth Accelerators and Market Barriers Table 35. Asia-Pacific Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 36. Central and South America Biologics Contract Manufacturing Investment Opportunities and Key Challenges Table 37. Central and South America Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 38. Middle East and Africa Biologics Contract Manufacturing Investment Opportunities and Key Challenges Table 39. Middle East and Africa Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 40. Lonza Group AG Corporation Information Table 41. Lonza Group AG Description and Major Businesses Table 42. Lonza Group AG Product Features and Attributes Table 43. Lonza Group AG Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Lonza Group AG Revenue Proportion by Product in 2025 Table 45. Lonza Group AG Revenue Proportion by Application in 2025 Table 46. Lonza Group AG Revenue Proportion by Geographic Area in 2025 Table 47. Lonza Group AG Biologics Contract Manufacturing SWOT Analysis Table 48. Lonza Group AG Recent Developments Table 49. Samsung Biologics Co., Ltd. Corporation Information Table 50. Samsung Biologics Co., Ltd. Description and Major Businesses Table 51. Samsung Biologics Co., Ltd. Product Features and Attributes Table 52. Samsung Biologics Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Samsung Biologics Co., Ltd. Revenue Proportion by Product in 2025 Table 54. Samsung Biologics Co., Ltd. Revenue Proportion by Application in 2025 Table 55. Samsung Biologics Co., Ltd. Revenue Proportion by Geographic Area in 2025 Table 56. Samsung Biologics Co., Ltd. Biologics Contract Manufacturing SWOT Analysis Table 57. Samsung Biologics Co., Ltd. Recent Developments Table 58. WuXi Biologics (Cayman) Inc. Corporation Information Table 59. WuXi Biologics (Cayman) Inc. Description and Major Businesses Table 60. WuXi Biologics (Cayman) Inc. Product Features and Attributes Table 61. WuXi Biologics (Cayman) Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. WuXi Biologics (Cayman) Inc. Revenue Proportion by Product in 2025 Table 63. WuXi Biologics (Cayman) Inc. Revenue Proportion by Application in 2025 Table 64. WuXi Biologics (Cayman) Inc. Revenue Proportion by Geographic Area in 2025 Table 65. WuXi Biologics (Cayman) Inc. Biologics Contract Manufacturing SWOT Analysis Table 66. WuXi Biologics (Cayman) Inc. Recent Developments Table 67. FUJIFILM Holdings Corporation Corporation Information Table 68. FUJIFILM Holdings Corporation Description and Major Businesses Table 69. FUJIFILM Holdings Corporation Product Features and Attributes Table 70. FUJIFILM Holdings Corporation Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. FUJIFILM Holdings Corporation Revenue Proportion by Product in 2025 Table 72. FUJIFILM Holdings Corporation Revenue Proportion by Application in 2025 Table 73. FUJIFILM Holdings Corporation Revenue Proportion by Geographic Area in 2025 Table 74. FUJIFILM Holdings Corporation Biologics Contract Manufacturing SWOT Analysis Table 75. FUJIFILM Holdings Corporation Recent Developments Table 76. AGC Inc. Corporation Information Table 77. AGC Inc. Description and Major Businesses Table 78. AGC Inc. Product Features and Attributes Table 79. AGC Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. AGC Inc. Revenue Proportion by Product in 2025 Table 81. AGC Inc. Revenue Proportion by Application in 2025 Table 82. AGC Inc. Revenue Proportion by Geographic Area in 2025 Table 83. AGC Inc. Biologics Contract Manufacturing SWOT Analysis Table 84. AGC Inc. Recent Developments Table 85. Boehringer Ingelheim International GmbH Corporation Information Table 86. Boehringer Ingelheim International GmbH Description and Major Businesses Table 87. Boehringer Ingelheim International GmbH Product Features and Attributes Table 88. Boehringer Ingelheim International GmbH Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Boehringer Ingelheim International GmbH Recent Developments Table 90. Thermo Fisher Scientific Inc. Corporation Information Table 91. Thermo Fisher Scientific Inc. Description and Major Businesses Table 92. Thermo Fisher Scientific Inc. Product Features and Attributes Table 93. Thermo Fisher Scientific Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Thermo Fisher Scientific Inc. Recent Developments Table 95. Novo Holdings A/S Corporation Information Table 96. Novo Holdings A/S Description and Major Businesses Table 97. Novo Holdings A/S Product Features and Attributes Table 98. Novo Holdings A/S Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Novo Holdings A/S Recent Developments Table 100. Rentschler Biopharma SE Corporation Information Table 101. Rentschler Biopharma SE Description and Major Businesses Table 102. Rentschler Biopharma SE Product Features and Attributes Table 103. Rentschler Biopharma SE Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Rentschler Biopharma SE Recent Developments Table 105. KBI Biopharma, Inc. Corporation Information Table 106. KBI Biopharma, Inc. Description and Major Businesses Table 107. KBI Biopharma, Inc. Product Features and Attributes Table 108. KBI Biopharma, Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. KBI Biopharma, Inc. Recent Developments Table 110. Ajinomoto Co., Inc. Corporation Information Table 111. Ajinomoto Co., Inc. Description and Major Businesses Table 112. Ajinomoto Co., Inc. Product Features and Attributes Table 113. Ajinomoto Co., Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Ajinomoto Co., Inc. Recent Developments Table 115. LOTTE BIOLOGICS Corporation Information Table 116. LOTTE BIOLOGICS Description and Major Businesses Table 117. LOTTE BIOLOGICS Product Features and Attributes Table 118. LOTTE BIOLOGICS Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. LOTTE BIOLOGICS Recent Developments Table 120. Polpharma Biologics Corporation Information Table 121. Polpharma Biologics Description and Major Businesses Table 122. Polpharma Biologics Product Features and Attributes Table 123. Polpharma Biologics Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Polpharma Biologics Recent Developments Table 125. EirGenix, Inc. Corporation Information Table 126. EirGenix, Inc. Description and Major Businesses Table 127. EirGenix, Inc. Product Features and Attributes Table 128. EirGenix, Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. EirGenix, Inc. Recent Developments Table 130. Richter-Helm BioLogics GmbH & Co. KG Corporation Information Table 131. Richter-Helm BioLogics GmbH & Co. KG Description and Major Businesses Table 132. Richter-Helm BioLogics GmbH & Co. KG Product Features and Attributes Table 133. Richter-Helm BioLogics GmbH & Co. KG Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Richter-Helm BioLogics GmbH & Co. KG Recent Developments Table 135. Simtra BioPharma Solutions Corporation Information Table 136. Simtra BioPharma Solutions Description and Major Businesses Table 137. Simtra BioPharma Solutions Product Features and Attributes Table 138. Simtra BioPharma Solutions Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Simtra BioPharma Solutions Recent Developments Table 140. Vetter Pharma-Fertigung GmbH & Co. KG Corporation Information Table 141. Vetter Pharma-Fertigung GmbH & Co. KG Description and Major Businesses Table 142. Vetter Pharma-Fertigung GmbH & Co. KG Product Features and Attributes Table 143. Vetter Pharma-Fertigung GmbH & Co. KG Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Vetter Pharma-Fertigung GmbH & Co. KG Recent Developments Table 145. Piramal Pharma Limited Corporation Information Table 146. Piramal Pharma Limited Description and Major Businesses Table 147. Piramal Pharma Limited Product Features and Attributes Table 148. Piramal Pharma Limited Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Piramal Pharma Limited Recent Developments Table 150. AbbVie Inc. Corporation Information Table 151. AbbVie Inc. Description and Major Businesses Table 152. AbbVie Inc. Product Features and Attributes Table 153. AbbVie Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. AbbVie Inc. Recent Developments Table 155. Emergent BioSolutions Inc. Corporation Information Table 156. Emergent BioSolutions Inc. Description and Major Businesses Table 157. Emergent BioSolutions Inc. Product Features and Attributes Table 158. Emergent BioSolutions Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 159. Emergent BioSolutions Inc. Recent Developments Table 160. SK pharmteco Corporation Information Table 161. SK pharmteco Description and Major Businesses Table 162. SK pharmteco Product Features and Attributes Table 163. SK pharmteco Revenue (US$ Million) and Gross Margin (2021-2026) Table 164. SK pharmteco Recent Developments Table 165. Oxford Biomedica plc Corporation Information Table 166. Oxford Biomedica plc Description and Major Businesses Table 167. Oxford Biomedica plc Product Features and Attributes Table 168. Oxford Biomedica plc Revenue (US$ Million) and Gross Margin (2021-2026) Table 169. Oxford Biomedica plc Recent Developments Table 170. WuXi XDC Cayman Inc. Corporation Information Table 171. WuXi XDC Cayman Inc. Description and Major Businesses Table 172. WuXi XDC Cayman Inc. Product Features and Attributes Table 173. WuXi XDC Cayman Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 174. WuXi XDC Cayman Inc. Recent Developments Table 175. Porton Pharma Solutions Ltd. Corporation Information Table 176. Porton Pharma Solutions Ltd. Description and Major Businesses Table 177. Porton Pharma Solutions Ltd. Product Features and Attributes Table 178. Porton Pharma Solutions Ltd. Revenue (US$ Million) and Gross Margin (2021-2026) Table 179. Porton Pharma Solutions Ltd. Recent Developments Table 180. Asymchem Laboratories (Tianjin) Co., Ltd. Corporation Information Table 181. Asymchem Laboratories (Tianjin) Co., Ltd. Description and Major Businesses Table 182. Asymchem Laboratories (Tianjin) Co., Ltd. Product Features and Attributes Table 183. Asymchem Laboratories (Tianjin) Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026) Table 184. Asymchem Laboratories (Tianjin) Co., Ltd. Recent Developments Table 185. BioVectra Inc. Corporation Information Table 186. BioVectra Inc. Description and Major Businesses Table 187. BioVectra Inc. Product Features and Attributes Table 188. BioVectra Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 189. BioVectra Inc. Recent Developments Table 190. Bora Pharmaceuticals Co., Ltd. Corporation Information Table 191. Bora Pharmaceuticals Co., Ltd. Description and Major Businesses Table 192. Bora Pharmaceuticals Co., Ltd. Product Features and Attributes Table 193. Bora Pharmaceuticals Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026) Table 194. Bora Pharmaceuticals Co., Ltd. Recent Developments Table 195. Recipharm AB Corporation Information Table 196. Recipharm AB Description and Major Businesses Table 197. Recipharm AB Product Features and Attributes Table 198. Recipharm AB Revenue (US$ Million) and Gross Margin (2021-2026) Table 199. Recipharm AB Recent Developments Table 200. Minaris Regenerative Medicine Corporation Information Table 201. Minaris Regenerative Medicine Description and Major Businesses Table 202. Minaris Regenerative Medicine Product Features and Attributes Table 203. Minaris Regenerative Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 204. Minaris Regenerative Medicine Recent Developments Table 205. Cellipont Bioservices Corporation Information Table 206. Cellipont Bioservices Description and Major Businesses Table 207. Cellipont Bioservices Product Features and Attributes Table 208. Cellipont Bioservices Revenue (US$ Million) and Gross Margin (2021-2026) Table 209. Cellipont Bioservices Recent Developments Table 210. Andelyn Biosciences Corporation Information Table 211. Andelyn Biosciences Description and Major Businesses Table 212. Andelyn Biosciences Product Features and Attributes Table 213. Andelyn Biosciences Revenue (US$ Million) and Gross Margin (2021-2026) Table 214. Andelyn Biosciences Recent Developments Table 215. Danaher Corporation Corporation Information Table 216. Danaher Corporation Description and Major Businesses Table 217. Danaher Corporation Product Features and Attributes Table 218. Danaher Corporation Revenue (US$ Million) and Gross Margin (2021-2026) Table 219. Danaher Corporation Recent Developments Table 220. BioCina Corporation Information Table 221. BioCina Description and Major Businesses Table 222. BioCina Product Features and Attributes Table 223. BioCina Revenue (US$ Million) and Gross Margin (2021-2026) Table 224. BioCina Recent Developments Table 225. Syngene International Limited Corporation Information Table 226. Syngene International Limited Description and Major Businesses Table 227. Syngene International Limited Product Features and Attributes Table 228. Syngene International Limited Revenue (US$ Million) and Gross Margin (2021-2026) Table 229. Syngene International Limited Recent Developments Table 230. Aragen Life Sciences Corporation Information Table 231. Aragen Life Sciences Description and Major Businesses Table 232. Aragen Life Sciences Product Features and Attributes Table 233. Aragen Life Sciences Revenue (US$ Million) and Gross Margin (2021-2026) Table 234. Aragen Life Sciences Recent Developments Table 235. MabPlex International Corporation Information Table 236. MabPlex International Description and Major Businesses Table 237. MabPlex International Product Features and Attributes Table 238. MabPlex International Revenue (US$ Million) and Gross Margin (2021-2026) Table 239. MabPlex International Recent Developments Table 240. GenScript Biotech Corporation Corporation Information Table 241. GenScript Biotech Corporation Description and Major Businesses Table 242. GenScript Biotech Corporation Product Features and Attributes Table 243. GenScript Biotech Corporation Revenue (US$ Million) and Gross Margin (2021-2026) Table 244. GenScript Biotech Corporation Recent Developments Table 245. Chime Biologics Corporation Information Table 246. Chime Biologics Description and Major Businesses Table 247. Chime Biologics Product Features and Attributes Table 248. Chime Biologics Revenue (US$ Million) and Gross Margin (2021-2026) Table 249. Chime Biologics Recent Developments Table 250. Hangzhou HJB Corporation Information Table 251. Hangzhou HJB Description and Major Businesses Table 252. Hangzhou HJB Product Features and Attributes Table 253. Hangzhou HJB Revenue (US$ Million) and Gross Margin (2021-2026) Table 254. Hangzhou HJB Recent Developments Table 255. BiBo Pharma Corporation Information Table 256. BiBo Pharma Description and Major Businesses Table 257. BiBo Pharma Product Features and Attributes Table 258. BiBo Pharma Revenue (US$ Million) and Gross Margin (2021-2026) Table 259. BiBo Pharma Recent Developments Table 260. Technologies, Platforms and Infrastructure Table 261. Distributors List Table 262. Market Trends and Market Evolution Table 263. Market Drivers and Opportunities Table 264. Market Challenges, Risks, and Restraints Table 265. Research Programs/Design for This Report Table 266. Key Data Information from Secondary Sources Table 267. Key Data Information from Primary Sources List of Figures Figure 1. Global Biologics Contract Manufacturing Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Figure 2. Monoclonal and Multispecific Antibodies Product Picture Figure 3. Antibody-Drug Conjugates (ADCs) Product Picture Figure 4. Vaccines Product Picture Figure 5. Cell Therapy Products Product Picture Figure 6. Gene Therapy and Viral Vector Products Product Picture Figure 7. Nucleic Acid Therapeutics Product Picture Figure 8. Others Product Picture Figure 9. Global Biologics Contract Manufacturing Market Size Growth Rate by Manufacturing Service Type 按, 2021 vs 2025 vs 2032 (US$ Million) Figure 10. Drug Substance Manufacturing Product Picture Figure 11. Drug Product Manufacturing Product Picture Figure 12. Integrated Drug Substance and Drug Product Manufacturing Product Picture Figure 13. Others Product Picture Figure 14. Global Biologics Contract Manufacturing Market Size Growth Rate by Development and Commercialization Stage, 2021 vs 2025 vs 2032 (US$ Million) Figure 15. Preclinical and IND-enabling Manufacturing Product Picture Figure 16. Phase I Clinical Manufacturing Product Picture Figure 17. Phase II Clinical Manufacturing Product Picture Figure 18. Phase III Clinical Manufacturing Product Picture Figure 19. Others Product Picture Figure 20. Global Biologics Contract Manufacturing Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Figure 21. Oncology Figure 22. Immunology and Autoimmune Diseases Figure 23. Infectious Diseases and Vaccines Figure 24. Metabolic and Endocrine Diseases Figure 25. Neurological Diseases Figure 26. Others Figure 27. Biologics Contract Manufacturing Report Years Considered Figure 28. Global Biologics Contract Manufacturing Revenue, (US$ Million), 2021 vs 2025 vs 2032 Figure 29. Global Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 30. Global Biologics Contract Manufacturing Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Figure 31. Global Biologics Contract Manufacturing Revenue-Based Market Share by Region (2021-2032) Figure 32. Global Biologics Contract Manufacturing Revenue-Based Market Share Ranking (2025) Figure 33. Tier Distribution by Revenue Contribution (2021 vs 2025) Figure 34. Monoclonal and Multispecific Antibodies Revenue-Based Market Share by Player in 2025 Figure 35. Antibody-Drug Conjugates (ADCs) Revenue-Based Market Share by Player in 2025 Figure 36. Vaccines Revenue-Based Market Share by Player in 2025 Figure 37. Cell Therapy Products Revenue-Based Market Share by Player in 2025 Figure 38. Gene Therapy and Viral Vector Products Revenue-Based Market Share by Player in 2025 Figure 39. Nucleic Acid Therapeutics Revenue-Based Market Share by Player in 2025 Figure 40. Others Revenue-Based Market Share by Player in 2025 Figure 41. Global Biologics Contract Manufacturing Revenue-Based Market Share by Type (2021-2032) Figure 42. Global Biologics Contract Manufacturing Revenue-Based Market Share by Manufacturing Service Type 按 (2021-2032) Figure 43. Global Biologics Contract Manufacturing Revenue-Based Market Share by Development and Commercialization Stage (2021-2032) Figure 44. Global Biologics Contract Manufacturing Revenue-Based Market Share by Application (2021-2032) Figure 45. North America Biologics Contract Manufacturing Revenue YoY (US$ Million), 2021-2032 Figure 46. North America Top 5 Players Biologics Contract Manufacturing Revenue (US$ Million) in 2025 Figure 47. North America Biologics Contract Manufacturing Revenue (US$ Million) by Application (2021-2032) Figure 48. US Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 49. Canada Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 50. Mexico Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 51. Europe Biologics Contract Manufacturing Revenue YoY (US$ Million), 2021-2032 Figure 52. Europe Top 5 Players Biologics Contract Manufacturing Revenue (US$ Million) in 2025 Figure 53. Europe Biologics Contract Manufacturing Revenue (US$ Million) by Application (2021-2032) Figure 54. Germany Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 55. France Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 56. U.K. Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 57. Italy Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 58. Russia Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 59. Asia-Pacific Biologics Contract Manufacturing Revenue YoY (US$ Million), 2021-2032 Figure 60. Asia-Pacific Top 8 Players Biologics Contract Manufacturing Revenue (US$ Million) in 2025 Figure 61. Asia-Pacific Biologics Contract Manufacturing Revenue (US$ Million) by Application (2021-2032) Figure 62. Indonesia Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 63. Japan Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 64. South Korea Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 65. Australia Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 66. India Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 67. Indonesia Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 68. Vietnam Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 69. Malaysia Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 70. Philippines Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 71. Singapore Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 72. Central and South America Biologics Contract Manufacturing Revenue YoY (US$ Million), 2021-2032 Figure 73. Central and South America Top 5 Players Biologics Contract Manufacturing Revenue (US$ Million) in 2025 Figure 74. Central and South America Biologics Contract Manufacturing Revenue (US$ Million) by Application (2021-2032) Figure 75. Brazil Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 76. Argentina Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 77. Middle East and Africa Biologics Contract Manufacturing Revenue YoY (US$ Million), 2021-2032 Figure 78. Middle East and Africa Top 5 Players Biologics Contract Manufacturing Revenue (US$ Million) in 2025 Figure 79. Middle East and Africa Biologics Contract Manufacturing Revenue (US$ Million) by Application (2021-2032) Figure 80. GCC Countries Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 81. Israel Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 82. Egypt Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 83. South Africa Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 84. Biologics Contract Manufacturing Value Chain Mapping Figure 85. Channels of Distribution (Direct Vs Distribution) Figure 86. Bottom-up and Top-down Approaches for This Report Figure 87. Data Triangulation Figure 88. Key Executives Interviewed
SummaryThe global Biologics Contract Manufacturing market is projected to grow from US$ 89453 million in 2025 to US$ 173452 million by 2032, at a CAGR of 9.9% (2026-2032), driven by critical product segments and diverse end‑use applications.Biologics Contract Manufacturing refers to specialized outsourced manufacturing services provided by contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) for biological pharmaceutical products. The industry focuses on GMP-compliant production of biological drug substances and finished drug products under contractual agreements with pharmaceutical companies, biotechnology developers, and other drug sponsors. Major product categories include monoclonal and multispecific antibodies, recombinant proteins, antibody-drug conjugates (ADCs), vaccines, cell therapy products, gene therapy and viral vector products, nucleic acid therapeutics, and other biologics. Core manufacturing technologies encompass mammalian cell culture, microbial fermentation, viral production, cell processing, nucleic acid manufacturing, bioconjugation, downstream purification, aseptic formulation, and fill-finish operations. Manufacturing services extend from preclinical and IND-enabling production through Phase I–III clinical manufacturing to commercial pharmaceutical supply. Important operational parameters include bioreactor capacity, production yield, process consistency, critical quality attributes, batch release performance, sterility assurance, and regulatory compliance. Biologics Contract Manufacturing supports drug development and commercialization across oncology, immunology, infectious diseases, metabolic and endocrine disorders, genetic diseases, and other therapeutic areas, providing pharmaceutical sponsors with specialized manufacturing infrastructure, technical expertise, and reliable biological medicine supply. Key Findings Biologics Contract Manufacturing focuses on outsourced GMP production of biological drug substances and finished drug products Monoclonal antibodies and recombinant proteins form an established foundation of biological contract manufacturing activities Commercial biologics manufacturing generates recurring production demand through approved medicines and long-term supply agreements North America, Europe, and Asia-Pacific are major regional centers for biological manufacturing and pharmaceutical outsourcing Market Trends The global Biologics Contract Manufacturing industry is evolving from traditional production outsourcing toward technologically specialized and integrated manufacturing partnerships covering multiple biological modalities and pharmaceutical development stages. Mammalian cell culture remains a foundational platform for antibody and recombinant protein manufacturing, while bispecific antibodies, ADCs, cell therapies, gene therapies, and nucleic acid therapeutics are introducing increasingly complex production requirements. Technology development is focused on high-productivity cell lines, intensified upstream processing, advanced purification systems, single-use bioreactors, automated quality monitoring, and digital manufacturing management. These technologies help manufacturers improve process consistency, increase productivity, and accommodate different batch sizes and production schedules. Pharmaceutical sponsors are also placing greater emphasis on manufacturing partners capable of coordinating drug substance production, formulation, sterile filling, and analytical support across the product lifecycle. This approach can reduce technology transfer complexity and strengthen continuity between clinical and commercial manufacturing. Another important trend is the growing demand for flexible manufacturing networks that combine established commercial production capacity with specialized facilities for emerging therapeutic modalities. The industry's long-term direction increasingly emphasizes manufacturing platform integration, operational transparency, product-specific technical expertise, and supply chain resilience rather than capacity expansion alone. Market Dynamics Drivers The principal growth drivers of Biologics Contract Manufacturing are expanding biological drug development pipelines, increasing manufacturing complexity, and the strategic importance of outsourcing within the pharmaceutical industry. Biological medicines require specialized facilities, validated production processes, highly trained personnel, and comprehensive quality management systems, creating substantial financial and technical barriers to establishing independent manufacturing operations. Outsourcing enables biotechnology developers to access established GMP capabilities while reducing upfront capital requirements and adjusting production commitments to clinical development progress. Large pharmaceutical companies also engage external manufacturers to supplement internal capacity, accelerate product launches, diversify manufacturing networks, and improve operational flexibility. Continued innovation in oncology, immunology, genetic diseases, and advanced therapies broadens the range of products requiring specialized manufacturing support. Regulatory requirements concerning manufacturing consistency, contamination prevention, product traceability, and supply reliability further strengthen demand for experienced manufacturing partners. The combination of clinical pipeline development and commercial supply requirements supports a diversified demand base across manufacturing stages. Restraints Biologics Contract Manufacturing is constrained by high capital requirements, complex manufacturing validation, specialized operating costs, and uncertainty surrounding customer development pipelines. Establishing GMP-compliant biologics manufacturing facilities requires substantial investment in cleanrooms, bioreactors, purification equipment, analytical laboratories, contamination control infrastructure, and supporting utilities. Operating expenses are affected by skilled personnel requirements, cell culture media, chromatography materials, single-use consumables, energy costs, and extensive quality assurance procedures. Newly installed production capacity generally requires facility qualification, customer technology transfer, process validation, and regulatory approval activities before reaching stable commercial utilization. Consequently, manufacturing expansion may involve a considerable period between capital expenditure and corresponding revenue generation. Clinical trial failures, development delays, and changes in pharmaceutical pipeline priorities can also lead to production rescheduling or contract modifications. Biological manufacturing processes are often highly product-specific, limiting the flexibility of transferring projects between facilities and increasing technical and financial costs associated with capacity reallocation. Opportunities Important opportunities in Biologics Contract Manufacturing are emerging from complex biological medicines, advanced therapeutic technologies, commercial production outsourcing, and geographical diversification of pharmaceutical supply chains. Increasing development activity involving bispecific and multispecific antibodies, ADCs, cell therapies, gene therapies, and nucleic acid therapeutics creates demand for specialized manufacturing technologies and integrated process capabilities. Contract manufacturers supporting projects from early clinical production through commercial supply can establish longer customer relationships and participate in successive manufacturing programs. Emerging biotechnology companies also represent an important customer group because they frequently require flexible GMP manufacturing capacity without making substantial investments in dedicated facilities. Technology-related opportunities include intensified cell culture, modular manufacturing infrastructure, automated production systems, advanced analytical platforms, and improved process monitoring. Additional opportunities arise from investment in regional manufacturing capacity across North America, Europe, and selected Asia-Pacific markets. Companies combining specialized biological manufacturing expertise, consistent regulatory compliance, efficient technology transfers, and dependable commercial supply capabilities are positioned to serve increasingly complex pharmaceutical manufacturing requirements. Challenges The major challenges facing Biologics Contract Manufacturing involve maintaining consistent product quality, managing capacity utilization, adapting to new therapeutic technologies, and operating across different regulatory environments. Biological production is sensitive to variations in cell culture conditions, raw material quality, process parameters, equipment performance, and contamination control. Manufacturing deviations, microbial contamination, unsuccessful validation campaigns, or product quality failures can result in batch losses, production delays, regulatory consequences, and substantial financial exposure. Transitioning from clinical to commercial manufacturing requires reliable process scale-up, reproducibility, and sustained compliance with strict quality requirements. Meanwhile, investments in emerging therapeutic platforms carry commercial uncertainty because individual drug development programs may be delayed or discontinued before reaching commercialization. Manufacturers must balance capacity expansion with customer diversification, technical specialization, and the risk of underutilized facilities. International operations introduce additional challenges associated with regulatory differences, technology transfer requirements, trade policies, and regional supply chain expectations. Maintaining experienced personnel, validated processes, transparent quality systems, and dependable customer relationships remains essential for sustainable competitiveness. Industry Chain Analysis The Biologics Contract Manufacturing industry chain consists of upstream bioprocessing materials and equipment suppliers, midstream contract manufacturers, and downstream pharmaceutical sponsors and therapeutic markets. Upstream participants provide cell culture media, feed supplements, chromatography resins, filtration membranes, single-use processing systems, bioreactors, analytical instruments, sterile containers, and specialized production components. The quality and availability of these inputs directly influence manufacturing productivity, process reliability, and final product consistency. Different biological modalities require distinct processing materials and manufacturing technologies, making supplier qualification, traceability, and contamination control important elements of the production system. Midstream manufacturing represents the principal value-creation stage, encompassing cell cultivation, fermentation, harvesting, purification, bioconjugation, formulation, aseptic filling, process validation, and quality testing. Contract manufacturers generate value through qualified GMP facilities, proprietary process technologies, regulatory expertise, manufacturing efficiency, and the ability to deliver consistent product quality across multiple batches. Downstream customers include multinational pharmaceutical companies, emerging biotechnology developers, and other biological medicine sponsors serving oncology, immunology, infectious diseases, metabolic disorders, and genetic diseases. The cost structure is influenced by facility depreciation, specialized labor, raw materials, manufacturing consumables, utilities, quality assurance, and regulatory compliance. Profitability depends on production yields, capacity utilization, project maturity, contract arrangements, and the balance between clinical and commercial manufacturing activities. Long-term commercial manufacturing agreements can improve production visibility, while clinical-stage projects create opportunities to establish relationships that may develop into recurring commercial supply contracts. Segment Insights By biological product category, monoclonal and multispecific antibodies, together with other recombinant proteins, represent an established foundation of the Biologics Contract Manufacturing industry. These products benefit from mature mammalian cell culture platforms, established downstream purification technologies, and extensive regulatory manufacturing experience. Increasing activity involving complex antibody structures and ADCs is creating demand for specialized technologies, including advanced protein expression, bioconjugation, high-containment processing, and analytical characterization. Cell and gene therapies constitute technically differentiated segments requiring dedicated manufacturing environments, viral vector capabilities, specialized quality controls, and production models adapted to small batches or patient-specific applications. Nucleic acid therapeutics and vaccines provide further opportunities for specialized manufacturing platforms. The resulting diversity of biological products creates different operational requirements, cost structures, and technical entry barriers across the industry. By manufacturing service type, drug substance production is a central activity covering upstream cultivation and downstream purification, while drug product manufacturing involves formulation, aseptic filling, lyophilization, and finished dosage preparation. Integrated manufacturing services coordinate these activities and can reduce technology transfer complexity. Mammalian cell culture and microbial fermentation remain important established platforms, while viral production, cellular manufacturing, nucleic acid technologies, and bioconjugation serve more specialized applications. Clinical-stage manufacturing typically emphasizes flexibility, technical support, and rapid project execution. Phase III and commercial manufacturing require more extensive process validation, batch reproducibility, regulatory readiness, and dependable production capacity. Commercial manufacturing can provide recurring demand, although revenue contribution and profitability vary according to production volumes, contractual arrangements, and facility utilization. The ability to support different biological modalities and development stages efficiently is becoming an increasingly important competitive capability. Downstream Market Opportunities Downstream opportunities for Biologics Contract Manufacturing are closely linked to biological drug innovation, commercialization, and increasingly diverse therapeutic applications. Oncology remains an important source of manufacturing demand through monoclonal antibodies, bispecific antibodies, ADCs, and cellular immunotherapies. Immunology and autoimmune diseases support recurring manufacturing requirements for commercial antibody and recombinant protein treatments. Infectious disease prevention and treatment generate demand for vaccines and specialized biological products, while metabolic and endocrine disorders create opportunities involving recombinant therapeutic proteins and other biological medicines. Rare and genetic diseases are particularly relevant to cell therapy, gene therapy, and viral vector manufacturing, where specialized production capabilities and stringent quality controls are essential. Customer requirements vary by pharmaceutical development stage and organizational scale. Large pharmaceutical companies generally prioritize production reliability, regulatory compliance, commercial manufacturing capacity, and long-term supply arrangements, while emerging biotechnology companies place greater emphasis on flexible production schedules, technical support, and access to specialized GMP infrastructure. These differences create opportunities for both integrated international manufacturers and specialized providers serving technically demanding therapeutic categories. Regional Insights North America, Europe, and Asia-Pacific represent the principal regional centers of Biologics Contract Manufacturing, supported by established pharmaceutical industries, biotechnology innovation, and specialized manufacturing infrastructure. North America benefits from a strong concentration of innovative pharmaceutical companies, biotechnology developers, and advanced therapy research organizations. The United States is an important source of outsourced manufacturing projects, particularly in oncology, antibody-based medicines, and emerging therapeutic modalities. Europe retains significant manufacturing capabilities through qualified GMP facilities, experienced technical personnel, established regulatory systems, and specialized production networks. Switzerland, Germany, and other European manufacturing locations play important roles in commercial biological production and complex contract manufacturing. Asia-Pacific has become increasingly important in the international biological manufacturing network. China has established extensive capabilities in mammalian cell culture, antibody manufacturing, and complex biological production, supporting domestic pharmaceutical developers and international customers. South Korea has developed large-scale manufacturing infrastructure for commercial biologics, particularly monoclonal antibodies and other mammalian cell-derived products. Japan maintains expertise in advanced bioprocessing technologies and specialized pharmaceutical manufacturing. India and other emerging Asian markets offer additional opportunities as domestic biotechnology activities and investment in GMP production facilities expand. Regional competition is influenced by manufacturing economics, regulatory recognition, technical capabilities, customer relationships, and localization policies. Pharmaceutical sponsors are increasingly evaluating geographical diversification, alternative manufacturing sites, and regional supply security, creating opportunities for established global providers and qualified regional manufacturers. Competitive Landscape Analysis The global Biologics Contract Manufacturing industry comprises large integrated CDMOs, specialized biologics manufacturers, pharmaceutical companies offering third-party manufacturing services, and technology-focused providers serving emerging therapeutic modalities. Lonza, Samsung Biologics, WuXi Biologics, FUJIFILM Holdings through its biologics manufacturing operations, AGC through AGC Biologics, and Boehringer Ingelheim through BioXcellence are important participants with established GMP manufacturing capabilities and international customer relationships. Lonza competes through integrated biologics manufacturing, specialized process technologies, and commercial production experience. Samsung Biologics emphasizes large-scale mammalian cell culture capacity, manufacturing execution, and long-term pharmaceutical supply partnerships. WuXi Biologics combines biological development and manufacturing capabilities with a broad project portfolio extending from early development to commercial production. In 2025, WuXi Biologics reported 945 integrated projects, including 74 Phase III projects and 25 commercial manufacturing projects. The company also added 209 new integrated projects, approximately two-thirds of which involved bispecific antibodies and ADCs, reflecting growing demand for complex biological modalities. Other established participants, including Rentschler Biopharma, KBI Biopharma, LOTTE BIOLOGICS, and specialized manufacturers of ADCs, viral vectors, and cell therapies, compete through technical capabilities, production quality, regulatory experience, and customer-specific manufacturing solutions. Industry competition increasingly emphasizes production efficiency, technology transfer performance, validated commercial capacity, regulatory compliance, and the ability to retain customer projects throughout the biological drug lifecycle. Strategic development is focused on integrated manufacturing platforms, specialized technologies, flexible production infrastructure, and geographically diversified supply networks, while long-term relationships with pharmaceutical sponsors remain an important source of competitive differentiation. Report Scope This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Biologics Contract Manufacturing market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers. By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern. Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends. Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths. A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand. Market Segmentation By Company Lonza Group AG Samsung Biologics Co., Ltd. WuXi Biologics (Cayman) Inc. FUJIFILM Holdings Corporation AGC Inc. Boehringer Ingelheim International GmbH Thermo Fisher Scientific Inc. Novo Holdings A/S Rentschler Biopharma SE KBI Biopharma, Inc. Ajinomoto Co., Inc. LOTTE BIOLOGICS Polpharma Biologics EirGenix, Inc. Richter-Helm BioLogics GmbH & Co. KG Simtra BioPharma Solutions Vetter Pharma-Fertigung GmbH & Co. KG Piramal Pharma Limited AbbVie Inc. Emergent BioSolutions Inc. SK pharmteco Oxford Biomedica plc WuXi XDC Cayman Inc. Porton Pharma Solutions Ltd. Asymchem Laboratories (Tianjin) Co., Ltd. BioVectra Inc. Bora Pharmaceuticals Co., Ltd. Recipharm AB Minaris Regenerative Medicine Cellipont Bioservices Andelyn Biosciences Danaher Corporation BioCina Syngene International Limited Aragen Life Sciences MabPlex International GenScript Biotech Corporation Chime Biologics Hangzhou HJB BiBo Pharma Segment by Type Monoclonal and Multispecific Antibodies Antibody-Drug Conjugates (ADCs) Vaccines Cell Therapy Products Gene Therapy and Viral Vector Products Nucleic Acid Therapeutics Others Segment by Manufacturing Service Type 按 Drug Substance Manufacturing Drug Product Manufacturing Integrated Drug Substance and Drug Product Manufacturing Others Segment by Development and Commercialization Stage Preclinical and IND-enabling Manufacturing Phase I Clinical Manufacturing Phase II Clinical Manufacturing Phase III Clinical Manufacturing Others Segment by Application Oncology Immunology and Autoimmune Diseases Infectious Diseases and Vaccines Metabolic and Endocrine Diseases Neurological Diseases Others Segment by Region North America United States Canada Mexico Asia-Pacific China Japan South Korea India Australia Vietnam Indonesia Malaysia Philippines Singapore Rest of Asia Europe Germany U.K. France Italy Spain Benelux Russia Rest of Europe Central and South America Brazil Argentina Rest of Central and South America Middle East & Africa GCC Countries Egypt Israel South Africa Rest of MEA Chapter Outline Chapter 1: Defines the Biologics Contract Manufacturing study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies Chapter 14: Actionable conclusions and strategic recommendations. Why This Report Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to: Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5). Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence. Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11). Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14). Leverage this 360° intelligence to turn market complexity into actionable competitive advantage. Table of Contents1 Study Coverage1.1 Introduction to Biologics Contract Manufacturing: Definition, Properties, and Key Attributes 1.2 Market Segmentation by Type 1.2.1 Global Biologics Contract Manufacturing Market Size by Type, 2021 vs 2025 vs 2032 1.2.2 Monoclonal and Multispecific Antibodies 1.2.3 Antibody-Drug Conjugates (ADCs) 1.2.4 Vaccines 1.2.5 Cell Therapy Products 1.2.6 Gene Therapy and Viral Vector Products 1.2.7 Nucleic Acid Therapeutics 1.2.8 Others 1.3 Market Segmentation by Manufacturing Service Type 按 1.3.1 Global Biologics Contract Manufacturing Market Size by Manufacturing Service Type 按, 2021 vs 2025 vs 2032 1.3.2 Drug Substance Manufacturing 1.3.3 Drug Product Manufacturing 1.3.4 Integrated Drug Substance and Drug Product Manufacturing 1.3.5 Others 1.4 Market Segmentation by Development and Commercialization Stage 1.4.1 Global Biologics Contract Manufacturing Market Size by Development and Commercialization Stage, 2021 vs 2025 vs 2032 1.4.2 Preclinical and IND-enabling Manufacturing 1.4.3 Phase I Clinical Manufacturing 1.4.4 Phase II Clinical Manufacturing 1.4.5 Phase III Clinical Manufacturing 1.4.6 Others 1.5 Market Segmentation by Application 1.5.1 Global Biologics Contract Manufacturing Market Size by Application, 2021 vs 2025 vs 2032 1.5.2 Oncology 1.5.3 Immunology and Autoimmune Diseases 1.5.4 Infectious Diseases and Vaccines 1.5.5 Metabolic and Endocrine Diseases 1.5.6 Neurological Diseases 1.5.7 Others 1.6 Assumptions and Limitations 1.7 Study Objectives 1.8 Years Considered 2 Executive Summary 2.1 Global Biologics Contract Manufacturing Revenue Estimates and Forecasts (2021-2032) 2.2 Global Biologics Contract Manufacturing Revenue by Region 2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032 2.2.2 Historical and Forecasted Revenue by Region (2021-2032) 2.2.3 Global Revenue-Based Market Share by Region (2021-2032) 2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends 3 Competitive Landscape 3.1 Global Biologics Contract Manufacturing Players’ Revenue Rankings and Profitability 3.1.1 Global Revenue (Value) by Players (2021-2026) 3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025) 3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3) 3.1.4 Gross Margin by Top Players (2021 vs 2025) 3.2 Global Biologics Contract Manufacturing Companies Headquarters and Service Footprint 3.3 Key Player Market Share by Product Type 3.3.1 Monoclonal and Multispecific Antibodies: Market Share by Key Players 3.3.2 Antibody-Drug Conjugates (ADCs): Market Share by Key Players 3.3.3 Vaccines: Market Share by Key Players 3.3.4 Cell Therapy Products: Market Share by Key Players 3.3.5 Gene Therapy and Viral Vector Products: Market Share by Key Players 3.3.6 Nucleic Acid Therapeutics: Market Share by Key Players 3.3.7 Others: Market Share by Key Players 3.4 Global Biologics Contract Manufacturing Market Concentration and Dynamics 3.4.1 Global Market Concentration 3.4.2 Market Entry and Exit Analysis 3.4.3 Strategic Moves: M&A, Expansion, R&D Investment 4 Product Segmentation 4.1 Global Biologics Contract Manufacturing Market by Type 4.1.1 Global Revenue by Type (2021-2032) 4.1.2 Global Revenue-Based Market Share by Type (2021-2032) 4.2 Global Biologics Contract Manufacturing Market by Manufacturing Service Type 按 4.2.1 Global Revenue by Manufacturing Service Type 按 (2021-2032) 4.2.2 Global Revenue-Based Market Share by Manufacturing Service Type 按 (2021-2032) 4.3 Global Biologics Contract Manufacturing Market by Development and Commercialization Stage 4.3.1 Global Revenue by Development and Commercialization Stage (2021-2032) 4.3.2 Global Revenue-Based Market Share by Development and Commercialization Stage (2021-2032) 4.4 Key Product Attributes and Differentiation 4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk 4.5.1 High-Growth Niches and Adoption Drivers 4.5.2 Profitability Hotspots and Cost Drivers 4.5.3 Substitution Threats 5 Downstream Applications and Customers 5.1 Global Biologics Contract Manufacturing Revenue by Application 5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032) 5.1.2 Revenue-Based Market Share by Application (2021-2032) 5.1.3 High-Growth Application Identification 5.1.4 Emerging Application Case Studies 5.2 Downstream Customer Analysis 5.2.1 Top Customers by Region 5.2.2 Top Customers by Application 6 North America 6.1 North America Market Size (2021-2032) 6.2 North America Key Players’ Revenue in 2025 6.3 North America Biologics Contract Manufacturing Market Size by Application (2021-2032) 6.4 North America Growth Accelerators and Market Barriers 6.5 North America Biologics Contract Manufacturing Market Size by Country 6.5.1 North America Revenue Trends by Country 6.5.2 US 6.5.3 Canada 6.5.4 Mexico 7 Europe 7.1 Europe Market Size (2021-2032) 7.2 Europe Key Players’ Revenue in 2025 7.3 Europe Biologics Contract Manufacturing Market Size by Application (2021-2032) 7.4 Europe Growth Accelerators and Market Barriers 7.5 Europe Biologics Contract Manufacturing Market Size by Country 7.5.1 Europe Revenue Trends by Country 7.5.2 Germany 7.5.3 France 7.5.4 U.K. 7.5.5 Italy 7.5.6 Russia 8 Asia-Pacific 8.1 Asia-Pacific Market Size (2021-2032) 8.2 Asia-Pacific Key Players’ Revenue in 2025 8.3 Asia-Pacific Biologics Contract Manufacturing Market Size by Application (2021-2032) 8.4 Asia-Pacific Growth Accelerators and Market Barriers 8.5 Asia-Pacific Biologics Contract Manufacturing Market Size by Region 8.5.1 Asia-Pacific Revenue Trends by Region 8.6 China 8.7 Japan 8.8 South Korea 8.9 Australia 8.10 India 8.11 Southeast Asia 8.11.1 Indonesia 8.11.2 Vietnam 8.11.3 Malaysia 8.11.4 Philippines 8.11.5 Singapore 9 Central and South America 9.1 Central and South America Market Size (2021-2032) 9.2 Central and South America Key Players’ Revenue in 2025 9.3 Central and South America Biologics Contract Manufacturing Market Size by Application (2021-2032) 9.4 Central and South America Investment Opportunities and Key Challenges 9.5 Central and South America Biologics Contract Manufacturing Market Size by Country 9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032) 9.5.2 Brazil 9.5.3 Argentina 10 Middle East and Africa 10.1 Middle East and Africa Market Size (2021-2032) 10.2 Middle East and Africa Key Players’ Revenue in 2025 10.3 Middle East and Africa Biologics Contract Manufacturing Market Size by Application (2021-2032) 10.4 Middle East and Africa Investment Opportunities and Key Challenges 10.5 Middle East and Africa Biologics Contract Manufacturing Market Size by Country 10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032) 10.5.2 GCC Countries 10.5.3 Israel 10.5.4 Egypt 10.5.5 South Africa 11 Corporate Profile 11.1 Lonza Group AG 11.1.1 Lonza Group AG Corporation Information 11.1.2 Lonza Group AG Business Overview 11.1.3 Lonza Group AG Biologics Contract Manufacturing Product Features and Attributes 11.1.4 Lonza Group AG Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.1.5 Lonza Group AG Biologics Contract Manufacturing Revenue by Product in 2025 11.1.6 Lonza Group AG Biologics Contract Manufacturing Revenue by Application in 2025 11.1.7 Lonza Group AG Biologics Contract Manufacturing Revenue by Geographic Area in 2025 11.1.8 Lonza Group AG Biologics Contract Manufacturing SWOT Analysis 11.1.9 Lonza Group AG Recent Developments 11.2 Samsung Biologics Co., Ltd. 11.2.1 Samsung Biologics Co., Ltd. Corporation Information 11.2.2 Samsung Biologics Co., Ltd. Business Overview 11.2.3 Samsung Biologics Co., Ltd. Biologics Contract Manufacturing Product Features and Attributes 11.2.4 Samsung Biologics Co., Ltd. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.2.5 Samsung Biologics Co., Ltd. Biologics Contract Manufacturing Revenue by Product in 2025 11.2.6 Samsung Biologics Co., Ltd. Biologics Contract Manufacturing Revenue by Application in 2025 11.2.7 Samsung Biologics Co., Ltd. Biologics Contract Manufacturing Revenue by Geographic Area in 2025 11.2.8 Samsung Biologics Co., Ltd. Biologics Contract Manufacturing SWOT Analysis 11.2.9 Samsung Biologics Co., Ltd. Recent Developments 11.3 WuXi Biologics (Cayman) Inc. 11.3.1 WuXi Biologics (Cayman) Inc. Corporation Information 11.3.2 WuXi Biologics (Cayman) Inc. Business Overview 11.3.3 WuXi Biologics (Cayman) Inc. Biologics Contract Manufacturing Product Features and Attributes 11.3.4 WuXi Biologics (Cayman) Inc. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.3.5 WuXi Biologics (Cayman) Inc. Biologics Contract Manufacturing Revenue by Product in 2025 11.3.6 WuXi Biologics (Cayman) Inc. Biologics Contract Manufacturing Revenue by Application in 2025 11.3.7 WuXi Biologics (Cayman) Inc. Biologics Contract Manufacturing Revenue by Geographic Area in 2025 11.3.8 WuXi Biologics (Cayman) Inc. Biologics Contract Manufacturing SWOT Analysis 11.3.9 WuXi Biologics (Cayman) Inc. Recent Developments 11.4 FUJIFILM Holdings Corporation 11.4.1 FUJIFILM Holdings Corporation Corporation Information 11.4.2 FUJIFILM Holdings Corporation Business Overview 11.4.3 FUJIFILM Holdings Corporation Biologics Contract Manufacturing Product Features and Attributes 11.4.4 FUJIFILM Holdings Corporation Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.4.5 FUJIFILM Holdings Corporation Biologics Contract Manufacturing Revenue by Product in 2025 11.4.6 FUJIFILM Holdings Corporation Biologics Contract Manufacturing Revenue by Application in 2025 11.4.7 FUJIFILM Holdings Corporation Biologics Contract Manufacturing Revenue by Geographic Area in 2025 11.4.8 FUJIFILM Holdings Corporation Biologics Contract Manufacturing SWOT Analysis 11.4.9 FUJIFILM Holdings Corporation Recent Developments 11.5 AGC Inc. 11.5.1 AGC Inc. Corporation Information 11.5.2 AGC Inc. Business Overview 11.5.3 AGC Inc. Biologics Contract Manufacturing Product Features and Attributes 11.5.4 AGC Inc. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.5.5 AGC Inc. Biologics Contract Manufacturing Revenue by Product in 2025 11.5.6 AGC Inc. Biologics Contract Manufacturing Revenue by Application in 2025 11.5.7 AGC Inc. Biologics Contract Manufacturing Revenue by Geographic Area in 2025 11.5.8 AGC Inc. Biologics Contract Manufacturing SWOT Analysis 11.5.9 AGC Inc. Recent Developments 11.6 Boehringer Ingelheim International GmbH 11.6.1 Boehringer Ingelheim International GmbH Corporation Information 11.6.2 Boehringer Ingelheim International GmbH Business Overview 11.6.3 Boehringer Ingelheim International GmbH Biologics Contract Manufacturing Product Features and Attributes 11.6.4 Boehringer Ingelheim International GmbH Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.6.5 Boehringer Ingelheim International GmbH Recent Developments 11.7 Thermo Fisher Scientific Inc. 11.7.1 Thermo Fisher Scientific Inc. Corporation Information 11.7.2 Thermo Fisher Scientific Inc. Business Overview 11.7.3 Thermo Fisher Scientific Inc. Biologics Contract Manufacturing Product Features and Attributes 11.7.4 Thermo Fisher Scientific Inc. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.7.5 Thermo Fisher Scientific Inc. Recent Developments 11.8 Novo Holdings A/S 11.8.1 Novo Holdings A/S Corporation Information 11.8.2 Novo Holdings A/S Business Overview 11.8.3 Novo Holdings A/S Biologics Contract Manufacturing Product Features and Attributes 11.8.4 Novo Holdings A/S Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.8.5 Novo Holdings A/S Recent Developments 11.9 Rentschler Biopharma SE 11.9.1 Rentschler Biopharma SE Corporation Information 11.9.2 Rentschler Biopharma SE Business Overview 11.9.3 Rentschler Biopharma SE Biologics Contract Manufacturing Product Features and Attributes 11.9.4 Rentschler Biopharma SE Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.9.5 Rentschler Biopharma SE Recent Developments 11.10 KBI Biopharma, Inc. 11.10.1 KBI Biopharma, Inc. Corporation Information 11.10.2 KBI Biopharma, Inc. Business Overview 11.10.3 KBI Biopharma, Inc. Biologics Contract Manufacturing Product Features and Attributes 11.10.4 KBI Biopharma, Inc. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.10.5 Company Ten Recent Developments 11.11 Ajinomoto Co., Inc. 11.11.1 Ajinomoto Co., Inc. Corporation Information 11.11.2 Ajinomoto Co., Inc. Business Overview 11.11.3 Ajinomoto Co., Inc. Biologics Contract Manufacturing Product Features and Attributes 11.11.4 Ajinomoto Co., Inc. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.11.5 Ajinomoto Co., Inc. Recent Developments 11.12 LOTTE BIOLOGICS 11.12.1 LOTTE BIOLOGICS Corporation Information 11.12.2 LOTTE BIOLOGICS Business Overview 11.12.3 LOTTE BIOLOGICS Biologics Contract Manufacturing Product Features and Attributes 11.12.4 LOTTE BIOLOGICS Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.12.5 LOTTE BIOLOGICS Recent Developments 11.13 Polpharma Biologics 11.13.1 Polpharma Biologics Corporation Information 11.13.2 Polpharma Biologics Business Overview 11.13.3 Polpharma Biologics Biologics Contract Manufacturing Product Features and Attributes 11.13.4 Polpharma Biologics Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.13.5 Polpharma Biologics Recent Developments 11.14 EirGenix, Inc. 11.14.1 EirGenix, Inc. Corporation Information 11.14.2 EirGenix, Inc. Business Overview 11.14.3 EirGenix, Inc. Biologics Contract Manufacturing Product Features and Attributes 11.14.4 EirGenix, Inc. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.14.5 EirGenix, Inc. Recent Developments 11.15 Richter-Helm BioLogics GmbH & Co. KG 11.15.1 Richter-Helm BioLogics GmbH & Co. KG Corporation Information 11.15.2 Richter-Helm BioLogics GmbH & Co. KG Business Overview 11.15.3 Richter-Helm BioLogics GmbH & Co. KG Biologics Contract Manufacturing Product Features and Attributes 11.15.4 Richter-Helm BioLogics GmbH & Co. KG Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.15.5 Richter-Helm BioLogics GmbH & Co. KG Recent Developments 11.16 Simtra BioPharma Solutions 11.16.1 Simtra BioPharma Solutions Corporation Information 11.16.2 Simtra BioPharma Solutions Business Overview 11.16.3 Simtra BioPharma Solutions Biologics Contract Manufacturing Product Features and Attributes 11.16.4 Simtra BioPharma Solutions Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.16.5 Simtra BioPharma Solutions Recent Developments 11.17 Vetter Pharma-Fertigung GmbH & Co. KG 11.17.1 Vetter Pharma-Fertigung GmbH & Co. KG Corporation Information 11.17.2 Vetter Pharma-Fertigung GmbH & Co. KG Business Overview 11.17.3 Vetter Pharma-Fertigung GmbH & Co. KG Biologics Contract Manufacturing Product Features and Attributes 11.17.4 Vetter Pharma-Fertigung GmbH & Co. KG Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.17.5 Vetter Pharma-Fertigung GmbH & Co. KG Recent Developments 11.18 Piramal Pharma Limited 11.18.1 Piramal Pharma Limited Corporation Information 11.18.2 Piramal Pharma Limited Business Overview 11.18.3 Piramal Pharma Limited Biologics Contract Manufacturing Product Features and Attributes 11.18.4 Piramal Pharma Limited Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.18.5 Piramal Pharma Limited Recent Developments 11.19 AbbVie Inc. 11.19.1 AbbVie Inc. Corporation Information 11.19.2 AbbVie Inc. Business Overview 11.19.3 AbbVie Inc. Biologics Contract Manufacturing Product Features and Attributes 11.19.4 AbbVie Inc. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.19.5 AbbVie Inc. Recent Developments 11.20 Emergent BioSolutions Inc. 11.20.1 Emergent BioSolutions Inc. Corporation Information 11.20.2 Emergent BioSolutions Inc. Business Overview 11.20.3 Emergent BioSolutions Inc. Biologics Contract Manufacturing Product Features and Attributes 11.20.4 Emergent BioSolutions Inc. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.20.5 Emergent BioSolutions Inc. Recent Developments 11.21 SK pharmteco 11.21.1 SK pharmteco Corporation Information 11.21.2 SK pharmteco Business Overview 11.21.3 SK pharmteco Biologics Contract Manufacturing Product Features and Attributes 11.21.4 SK pharmteco Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.21.5 SK pharmteco Recent Developments 11.22 Oxford Biomedica plc 11.22.1 Oxford Biomedica plc Corporation Information 11.22.2 Oxford Biomedica plc Business Overview 11.22.3 Oxford Biomedica plc Biologics Contract Manufacturing Product Features and Attributes 11.22.4 Oxford Biomedica plc Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.22.5 Oxford Biomedica plc Recent Developments 11.23 WuXi XDC Cayman Inc. 11.23.1 WuXi XDC Cayman Inc. Corporation Information 11.23.2 WuXi XDC Cayman Inc. Business Overview 11.23.3 WuXi XDC Cayman Inc. Biologics Contract Manufacturing Product Features and Attributes 11.23.4 WuXi XDC Cayman Inc. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.23.5 WuXi XDC Cayman Inc. Recent Developments 11.24 Porton Pharma Solutions Ltd. 11.24.1 Porton Pharma Solutions Ltd. Corporation Information 11.24.2 Porton Pharma Solutions Ltd. Business Overview 11.24.3 Porton Pharma Solutions Ltd. Biologics Contract Manufacturing Product Features and Attributes 11.24.4 Porton Pharma Solutions Ltd. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.24.5 Porton Pharma Solutions Ltd. Recent Developments 11.25 Asymchem Laboratories (Tianjin) Co., Ltd. 11.25.1 Asymchem Laboratories (Tianjin) Co., Ltd. Corporation Information 11.25.2 Asymchem Laboratories (Tianjin) Co., Ltd. Business Overview 11.25.3 Asymchem Laboratories (Tianjin) Co., Ltd. Biologics Contract Manufacturing Product Features and Attributes 11.25.4 Asymchem Laboratories (Tianjin) Co., Ltd. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.25.5 Asymchem Laboratories (Tianjin) Co., Ltd. Recent Developments 11.26 BioVectra Inc. 11.26.1 BioVectra Inc. Corporation Information 11.26.2 BioVectra Inc. Business Overview 11.26.3 BioVectra Inc. Biologics Contract Manufacturing Product Features and Attributes 11.26.4 BioVectra Inc. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.26.5 BioVectra Inc. Recent Developments 11.27 Bora Pharmaceuticals Co., Ltd. 11.27.1 Bora Pharmaceuticals Co., Ltd. Corporation Information 11.27.2 Bora Pharmaceuticals Co., Ltd. Business Overview 11.27.3 Bora Pharmaceuticals Co., Ltd. Biologics Contract Manufacturing Product Features and Attributes 11.27.4 Bora Pharmaceuticals Co., Ltd. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.27.5 Bora Pharmaceuticals Co., Ltd. Recent Developments 11.28 Recipharm AB 11.28.1 Recipharm AB Corporation Information 11.28.2 Recipharm AB Business Overview 11.28.3 Recipharm AB Biologics Contract Manufacturing Product Features and Attributes 11.28.4 Recipharm AB Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.28.5 Recipharm AB Recent Developments 11.29 Minaris Regenerative Medicine 11.29.1 Minaris Regenerative Medicine Corporation Information 11.29.2 Minaris Regenerative Medicine Business Overview 11.29.3 Minaris Regenerative Medicine Biologics Contract Manufacturing Product Features and Attributes 11.29.4 Minaris Regenerative Medicine Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.29.5 Minaris Regenerative Medicine Recent Developments 11.30 Cellipont Bioservices 11.30.1 Cellipont Bioservices Corporation Information 11.30.2 Cellipont Bioservices Business Overview 11.30.3 Cellipont Bioservices Biologics Contract Manufacturing Product Features and Attributes 11.30.4 Cellipont Bioservices Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.30.5 Cellipont Bioservices Recent Developments 11.31 Andelyn Biosciences 11.31.1 Andelyn Biosciences Corporation Information 11.31.2 Andelyn Biosciences Business Overview 11.31.3 Andelyn Biosciences Biologics Contract Manufacturing Product Features and Attributes 11.31.4 Andelyn Biosciences Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.31.5 Andelyn Biosciences Recent Developments 11.32 Danaher Corporation 11.32.1 Danaher Corporation Corporation Information 11.32.2 Danaher Corporation Business Overview 11.32.3 Danaher Corporation Biologics Contract Manufacturing Product Features and Attributes 11.32.4 Danaher Corporation Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.32.5 Danaher Corporation Recent Developments 11.33 BioCina 11.33.1 BioCina Corporation Information 11.33.2 BioCina Business Overview 11.33.3 BioCina Biologics Contract Manufacturing Product Features and Attributes 11.33.4 BioCina Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.33.5 BioCina Recent Developments 11.34 Syngene International Limited 11.34.1 Syngene International Limited Corporation Information 11.34.2 Syngene International Limited Business Overview 11.34.3 Syngene International Limited Biologics Contract Manufacturing Product Features and Attributes 11.34.4 Syngene International Limited Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.34.5 Syngene International Limited Recent Developments 11.35 Aragen Life Sciences 11.35.1 Aragen Life Sciences Corporation Information 11.35.2 Aragen Life Sciences Business Overview 11.35.3 Aragen Life Sciences Biologics Contract Manufacturing Product Features and Attributes 11.35.4 Aragen Life Sciences Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.35.5 Aragen Life Sciences Recent Developments 11.36 MabPlex International 11.36.1 MabPlex International Corporation Information 11.36.2 MabPlex International Business Overview 11.36.3 MabPlex International Biologics Contract Manufacturing Product Features and Attributes 11.36.4 MabPlex International Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.36.5 MabPlex International Recent Developments 11.37 GenScript Biotech Corporation 11.37.1 GenScript Biotech Corporation Corporation Information 11.37.2 GenScript Biotech Corporation Business Overview 11.37.3 GenScript Biotech Corporation Biologics Contract Manufacturing Product Features and Attributes 11.37.4 GenScript Biotech Corporation Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.37.5 GenScript Biotech Corporation Recent Developments 11.38 Chime Biologics 11.38.1 Chime Biologics Corporation Information 11.38.2 Chime Biologics Business Overview 11.38.3 Chime Biologics Biologics Contract Manufacturing Product Features and Attributes 11.38.4 Chime Biologics Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.38.5 Chime Biologics Recent Developments 11.39 Hangzhou HJB 11.39.1 Hangzhou HJB Corporation Information 11.39.2 Hangzhou HJB Business Overview 11.39.3 Hangzhou HJB Biologics Contract Manufacturing Product Features and Attributes 11.39.4 Hangzhou HJB Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.39.5 Hangzhou HJB Recent Developments 11.40 BiBo Pharma 11.40.1 BiBo Pharma Corporation Information 11.40.2 BiBo Pharma Business Overview 11.40.3 BiBo Pharma Biologics Contract Manufacturing Product Features and Attributes 11.40.4 BiBo Pharma Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026) 11.40.5 BiBo Pharma Recent Developments 12 Biologics Contract Manufacturing Value Chain and Ecosystem Analysis 12.1 Biologics Contract Manufacturing Value Chain (Ecosystem Structure) 12.2 Upstream Analysis 12.2.1 Key Technologies, Platforms and Infrastructure 12.3 Midstream Analysis 12.4 Downstream Sales Model and Distribution Networks 12.4.1 Sales Channels 12.4.2 Distributors 13 Biologics Contract Manufacturing Market Dynamics 13.1 Industry Trends and Evolution 13.2 Market Growth Drivers and Emerging Opportunities 13.3 Market Challenges, Risks, and Restraints 14 Key Findings in the Global Biologics Contract Manufacturing Study 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.1.1 Research Programs/Design 15.1.1.2 Market Size Estimation 15.1.1.3 Market Breakdown and Data Triangulation 15.1.2 Data Source 15.1.2.1 Secondary Sources 15.1.2.2 Primary Sources 15.2 Author Details List of Tables/GraphsList of TablesTable 1. Global Biologics Contract Manufacturing Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Table 2. Global Biologics Contract Manufacturing Market Size Growth Rate by Manufacturing Service Type 按, 2021 vs 2025 vs 2032 (US$ Million) Table 3. Global Biologics Contract Manufacturing Market Size Growth Rate by Development and Commercialization Stage, 2021 vs 2025 vs 2032 (US$ Million) Table 4. Global Biologics Contract Manufacturing Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Table 5. Global Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 6. Global Biologics Contract Manufacturing Revenue by Region (US$ Million), 2021-2026 Table 7. Global Biologics Contract Manufacturing Revenue by Region (US$ Million), 2027-2032 Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 9. Global Biologics Contract Manufacturing Revenue by Players (US$ Million), 2021-2026 Table 10. Global Biologics Contract Manufacturing Revenue-Based Market Share by Players (2021-2026) Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue) Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Biologics Contract Manufacturing Revenue, 2025 Table 13. Global Biologics Contract Manufacturing Average Gross Margin (%) by Player (2021 vs 2025) Table 14. Global Biologics Contract Manufacturing Companies Headquarters Table 15. Global Biologics Contract Manufacturing Market Concentration Ratio (CR5) Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment Table 18. Global Biologics Contract Manufacturing Revenue by Type (US$ Million), 2021-2026 Table 19. Global Biologics Contract Manufacturing Revenue by Type (US$ Million), 2027-2032 Table 20. Global Biologics Contract Manufacturing Revenue by Manufacturing Service Type 按 (US$ Million), 2021-2026 Table 21. Global Biologics Contract Manufacturing Revenue by Manufacturing Service Type 按 (US$ Million), 2027-2032 Table 22. Global Biologics Contract Manufacturing Revenue by Development and Commercialization Stage (US$ Million), 2021-2026 Table 23. Global Biologics Contract Manufacturing Revenue by Development and Commercialization Stage (US$ Million), 2027-2032 Table 24. Key Product Attributes and Differentiation Table 25. Global Biologics Contract Manufacturing Revenue by Application (US$ Million), 2021-2026 Table 26. Global Biologics Contract Manufacturing Revenue by Application (US$ Million), 2027-2032 Table 27. Biologics Contract Manufacturing High-Growth Sectors Demand CAGR (2026-2032) Table 28. Top Customers by Region Table 29. Top Customers by Application Table 30. North America Biologics Contract Manufacturing Growth Accelerators and Market Barriers Table 31. North America Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 32. Europe Biologics Contract Manufacturing Growth Accelerators and Market Barriers Table 33. Europe Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million) Table 34. Asia-Pacific Biologics Contract Manufacturing Growth Accelerators and Market Barriers Table 35. Asia-Pacific Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 36. Central and South America Biologics Contract Manufacturing Investment Opportunities and Key Challenges Table 37. Central and South America Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 38. Middle East and Africa Biologics Contract Manufacturing Investment Opportunities and Key Challenges Table 39. Middle East and Africa Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 40. Lonza Group AG Corporation Information Table 41. Lonza Group AG Description and Major Businesses Table 42. Lonza Group AG Product Features and Attributes Table 43. Lonza Group AG Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Lonza Group AG Revenue Proportion by Product in 2025 Table 45. Lonza Group AG Revenue Proportion by Application in 2025 Table 46. Lonza Group AG Revenue Proportion by Geographic Area in 2025 Table 47. Lonza Group AG Biologics Contract Manufacturing SWOT Analysis Table 48. Lonza Group AG Recent Developments Table 49. Samsung Biologics Co., Ltd. Corporation Information Table 50. Samsung Biologics Co., Ltd. Description and Major Businesses Table 51. Samsung Biologics Co., Ltd. Product Features and Attributes Table 52. Samsung Biologics Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Samsung Biologics Co., Ltd. Revenue Proportion by Product in 2025 Table 54. Samsung Biologics Co., Ltd. Revenue Proportion by Application in 2025 Table 55. Samsung Biologics Co., Ltd. Revenue Proportion by Geographic Area in 2025 Table 56. Samsung Biologics Co., Ltd. Biologics Contract Manufacturing SWOT Analysis Table 57. Samsung Biologics Co., Ltd. Recent Developments Table 58. WuXi Biologics (Cayman) Inc. Corporation Information Table 59. WuXi Biologics (Cayman) Inc. Description and Major Businesses Table 60. WuXi Biologics (Cayman) Inc. Product Features and Attributes Table 61. WuXi Biologics (Cayman) Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. WuXi Biologics (Cayman) Inc. Revenue Proportion by Product in 2025 Table 63. WuXi Biologics (Cayman) Inc. Revenue Proportion by Application in 2025 Table 64. WuXi Biologics (Cayman) Inc. Revenue Proportion by Geographic Area in 2025 Table 65. WuXi Biologics (Cayman) Inc. Biologics Contract Manufacturing SWOT Analysis Table 66. WuXi Biologics (Cayman) Inc. Recent Developments Table 67. FUJIFILM Holdings Corporation Corporation Information Table 68. FUJIFILM Holdings Corporation Description and Major Businesses Table 69. FUJIFILM Holdings Corporation Product Features and Attributes Table 70. FUJIFILM Holdings Corporation Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. FUJIFILM Holdings Corporation Revenue Proportion by Product in 2025 Table 72. FUJIFILM Holdings Corporation Revenue Proportion by Application in 2025 Table 73. FUJIFILM Holdings Corporation Revenue Proportion by Geographic Area in 2025 Table 74. FUJIFILM Holdings Corporation Biologics Contract Manufacturing SWOT Analysis Table 75. FUJIFILM Holdings Corporation Recent Developments Table 76. AGC Inc. Corporation Information Table 77. AGC Inc. Description and Major Businesses Table 78. AGC Inc. Product Features and Attributes Table 79. AGC Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. AGC Inc. Revenue Proportion by Product in 2025 Table 81. AGC Inc. Revenue Proportion by Application in 2025 Table 82. AGC Inc. Revenue Proportion by Geographic Area in 2025 Table 83. AGC Inc. Biologics Contract Manufacturing SWOT Analysis Table 84. AGC Inc. Recent Developments Table 85. Boehringer Ingelheim International GmbH Corporation Information Table 86. Boehringer Ingelheim International GmbH Description and Major Businesses Table 87. Boehringer Ingelheim International GmbH Product Features and Attributes Table 88. Boehringer Ingelheim International GmbH Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Boehringer Ingelheim International GmbH Recent Developments Table 90. Thermo Fisher Scientific Inc. Corporation Information Table 91. Thermo Fisher Scientific Inc. Description and Major Businesses Table 92. Thermo Fisher Scientific Inc. Product Features and Attributes Table 93. Thermo Fisher Scientific Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Thermo Fisher Scientific Inc. Recent Developments Table 95. Novo Holdings A/S Corporation Information Table 96. Novo Holdings A/S Description and Major Businesses Table 97. Novo Holdings A/S Product Features and Attributes Table 98. Novo Holdings A/S Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Novo Holdings A/S Recent Developments Table 100. Rentschler Biopharma SE Corporation Information Table 101. Rentschler Biopharma SE Description and Major Businesses Table 102. Rentschler Biopharma SE Product Features and Attributes Table 103. Rentschler Biopharma SE Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Rentschler Biopharma SE Recent Developments Table 105. KBI Biopharma, Inc. Corporation Information Table 106. KBI Biopharma, Inc. Description and Major Businesses Table 107. KBI Biopharma, Inc. Product Features and Attributes Table 108. KBI Biopharma, Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. KBI Biopharma, Inc. Recent Developments Table 110. Ajinomoto Co., Inc. Corporation Information Table 111. Ajinomoto Co., Inc. Description and Major Businesses Table 112. Ajinomoto Co., Inc. Product Features and Attributes Table 113. Ajinomoto Co., Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Ajinomoto Co., Inc. Recent Developments Table 115. LOTTE BIOLOGICS Corporation Information Table 116. LOTTE BIOLOGICS Description and Major Businesses Table 117. LOTTE BIOLOGICS Product Features and Attributes Table 118. LOTTE BIOLOGICS Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. LOTTE BIOLOGICS Recent Developments Table 120. Polpharma Biologics Corporation Information Table 121. Polpharma Biologics Description and Major Businesses Table 122. Polpharma Biologics Product Features and Attributes Table 123. Polpharma Biologics Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Polpharma Biologics Recent Developments Table 125. EirGenix, Inc. Corporation Information Table 126. EirGenix, Inc. Description and Major Businesses Table 127. EirGenix, Inc. Product Features and Attributes Table 128. EirGenix, Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. EirGenix, Inc. Recent Developments Table 130. Richter-Helm BioLogics GmbH & Co. KG Corporation Information Table 131. Richter-Helm BioLogics GmbH & Co. KG Description and Major Businesses Table 132. Richter-Helm BioLogics GmbH & Co. KG Product Features and Attributes Table 133. Richter-Helm BioLogics GmbH & Co. KG Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Richter-Helm BioLogics GmbH & Co. KG Recent Developments Table 135. Simtra BioPharma Solutions Corporation Information Table 136. Simtra BioPharma Solutions Description and Major Businesses Table 137. Simtra BioPharma Solutions Product Features and Attributes Table 138. Simtra BioPharma Solutions Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Simtra BioPharma Solutions Recent Developments Table 140. Vetter Pharma-Fertigung GmbH & Co. KG Corporation Information Table 141. Vetter Pharma-Fertigung GmbH & Co. KG Description and Major Businesses Table 142. Vetter Pharma-Fertigung GmbH & Co. KG Product Features and Attributes Table 143. Vetter Pharma-Fertigung GmbH & Co. KG Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Vetter Pharma-Fertigung GmbH & Co. KG Recent Developments Table 145. Piramal Pharma Limited Corporation Information Table 146. Piramal Pharma Limited Description and Major Businesses Table 147. Piramal Pharma Limited Product Features and Attributes Table 148. Piramal Pharma Limited Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Piramal Pharma Limited Recent Developments Table 150. AbbVie Inc. Corporation Information Table 151. AbbVie Inc. Description and Major Businesses Table 152. AbbVie Inc. Product Features and Attributes Table 153. AbbVie Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. AbbVie Inc. Recent Developments Table 155. Emergent BioSolutions Inc. Corporation Information Table 156. Emergent BioSolutions Inc. Description and Major Businesses Table 157. Emergent BioSolutions Inc. Product Features and Attributes Table 158. Emergent BioSolutions Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 159. Emergent BioSolutions Inc. Recent Developments Table 160. SK pharmteco Corporation Information Table 161. SK pharmteco Description and Major Businesses Table 162. SK pharmteco Product Features and Attributes Table 163. SK pharmteco Revenue (US$ Million) and Gross Margin (2021-2026) Table 164. SK pharmteco Recent Developments Table 165. Oxford Biomedica plc Corporation Information Table 166. Oxford Biomedica plc Description and Major Businesses Table 167. Oxford Biomedica plc Product Features and Attributes Table 168. Oxford Biomedica plc Revenue (US$ Million) and Gross Margin (2021-2026) Table 169. Oxford Biomedica plc Recent Developments Table 170. WuXi XDC Cayman Inc. Corporation Information Table 171. WuXi XDC Cayman Inc. Description and Major Businesses Table 172. WuXi XDC Cayman Inc. Product Features and Attributes Table 173. WuXi XDC Cayman Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 174. WuXi XDC Cayman Inc. Recent Developments Table 175. Porton Pharma Solutions Ltd. Corporation Information Table 176. Porton Pharma Solutions Ltd. Description and Major Businesses Table 177. Porton Pharma Solutions Ltd. Product Features and Attributes Table 178. Porton Pharma Solutions Ltd. Revenue (US$ Million) and Gross Margin (2021-2026) Table 179. Porton Pharma Solutions Ltd. Recent Developments Table 180. Asymchem Laboratories (Tianjin) Co., Ltd. Corporation Information Table 181. Asymchem Laboratories (Tianjin) Co., Ltd. Description and Major Businesses Table 182. Asymchem Laboratories (Tianjin) Co., Ltd. Product Features and Attributes Table 183. Asymchem Laboratories (Tianjin) Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026) Table 184. Asymchem Laboratories (Tianjin) Co., Ltd. Recent Developments Table 185. BioVectra Inc. Corporation Information Table 186. BioVectra Inc. Description and Major Businesses Table 187. BioVectra Inc. Product Features and Attributes Table 188. BioVectra Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 189. BioVectra Inc. Recent Developments Table 190. Bora Pharmaceuticals Co., Ltd. Corporation Information Table 191. Bora Pharmaceuticals Co., Ltd. Description and Major Businesses Table 192. Bora Pharmaceuticals Co., Ltd. Product Features and Attributes Table 193. Bora Pharmaceuticals Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026) Table 194. Bora Pharmaceuticals Co., Ltd. Recent Developments Table 195. Recipharm AB Corporation Information Table 196. Recipharm AB Description and Major Businesses Table 197. Recipharm AB Product Features and Attributes Table 198. Recipharm AB Revenue (US$ Million) and Gross Margin (2021-2026) Table 199. Recipharm AB Recent Developments Table 200. Minaris Regenerative Medicine Corporation Information Table 201. Minaris Regenerative Medicine Description and Major Businesses Table 202. Minaris Regenerative Medicine Product Features and Attributes Table 203. Minaris Regenerative Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 204. Minaris Regenerative Medicine Recent Developments Table 205. Cellipont Bioservices Corporation Information Table 206. Cellipont Bioservices Description and Major Businesses Table 207. Cellipont Bioservices Product Features and Attributes Table 208. Cellipont Bioservices Revenue (US$ Million) and Gross Margin (2021-2026) Table 209. Cellipont Bioservices Recent Developments Table 210. Andelyn Biosciences Corporation Information Table 211. Andelyn Biosciences Description and Major Businesses Table 212. Andelyn Biosciences Product Features and Attributes Table 213. Andelyn Biosciences Revenue (US$ Million) and Gross Margin (2021-2026) Table 214. Andelyn Biosciences Recent Developments Table 215. Danaher Corporation Corporation Information Table 216. Danaher Corporation Description and Major Businesses Table 217. Danaher Corporation Product Features and Attributes Table 218. Danaher Corporation Revenue (US$ Million) and Gross Margin (2021-2026) Table 219. Danaher Corporation Recent Developments Table 220. BioCina Corporation Information Table 221. BioCina Description and Major Businesses Table 222. BioCina Product Features and Attributes Table 223. BioCina Revenue (US$ Million) and Gross Margin (2021-2026) Table 224. BioCina Recent Developments Table 225. Syngene International Limited Corporation Information Table 226. Syngene International Limited Description and Major Businesses Table 227. Syngene International Limited Product Features and Attributes Table 228. Syngene International Limited Revenue (US$ Million) and Gross Margin (2021-2026) Table 229. Syngene International Limited Recent Developments Table 230. Aragen Life Sciences Corporation Information Table 231. Aragen Life Sciences Description and Major Businesses Table 232. Aragen Life Sciences Product Features and Attributes Table 233. Aragen Life Sciences Revenue (US$ Million) and Gross Margin (2021-2026) Table 234. Aragen Life Sciences Recent Developments Table 235. MabPlex International Corporation Information Table 236. MabPlex International Description and Major Businesses Table 237. MabPlex International Product Features and Attributes Table 238. MabPlex International Revenue (US$ Million) and Gross Margin (2021-2026) Table 239. MabPlex International Recent Developments Table 240. GenScript Biotech Corporation Corporation Information Table 241. GenScript Biotech Corporation Description and Major Businesses Table 242. GenScript Biotech Corporation Product Features and Attributes Table 243. GenScript Biotech Corporation Revenue (US$ Million) and Gross Margin (2021-2026) Table 244. GenScript Biotech Corporation Recent Developments Table 245. Chime Biologics Corporation Information Table 246. Chime Biologics Description and Major Businesses Table 247. Chime Biologics Product Features and Attributes Table 248. Chime Biologics Revenue (US$ Million) and Gross Margin (2021-2026) Table 249. Chime Biologics Recent Developments Table 250. Hangzhou HJB Corporation Information Table 251. Hangzhou HJB Description and Major Businesses Table 252. Hangzhou HJB Product Features and Attributes Table 253. Hangzhou HJB Revenue (US$ Million) and Gross Margin (2021-2026) Table 254. Hangzhou HJB Recent Developments Table 255. BiBo Pharma Corporation Information Table 256. BiBo Pharma Description and Major Businesses Table 257. BiBo Pharma Product Features and Attributes Table 258. BiBo Pharma Revenue (US$ Million) and Gross Margin (2021-2026) Table 259. BiBo Pharma Recent Developments Table 260. Technologies, Platforms and Infrastructure Table 261. Distributors List Table 262. Market Trends and Market Evolution Table 263. Market Drivers and Opportunities Table 264. Market Challenges, Risks, and Restraints Table 265. Research Programs/Design for This Report Table 266. Key Data Information from Secondary Sources Table 267. Key Data Information from Primary Sources List of Figures Figure 1. Global Biologics Contract Manufacturing Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Figure 2. Monoclonal and Multispecific Antibodies Product Picture Figure 3. Antibody-Drug Conjugates (ADCs) Product Picture Figure 4. Vaccines Product Picture Figure 5. Cell Therapy Products Product Picture Figure 6. Gene Therapy and Viral Vector Products Product Picture Figure 7. Nucleic Acid Therapeutics Product Picture Figure 8. Others Product Picture Figure 9. Global Biologics Contract Manufacturing Market Size Growth Rate by Manufacturing Service Type 按, 2021 vs 2025 vs 2032 (US$ Million) Figure 10. Drug Substance Manufacturing Product Picture Figure 11. Drug Product Manufacturing Product Picture Figure 12. Integrated Drug Substance and Drug Product Manufacturing Product Picture Figure 13. Others Product Picture Figure 14. Global Biologics Contract Manufacturing Market Size Growth Rate by Development and Commercialization Stage, 2021 vs 2025 vs 2032 (US$ Million) Figure 15. Preclinical and IND-enabling Manufacturing Product Picture Figure 16. Phase I Clinical Manufacturing Product Picture Figure 17. Phase II Clinical Manufacturing Product Picture Figure 18. Phase III Clinical Manufacturing Product Picture Figure 19. Others Product Picture Figure 20. Global Biologics Contract Manufacturing Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Figure 21. Oncology Figure 22. Immunology and Autoimmune Diseases Figure 23. Infectious Diseases and Vaccines Figure 24. Metabolic and Endocrine Diseases Figure 25. Neurological Diseases Figure 26. Others Figure 27. Biologics Contract Manufacturing Report Years Considered Figure 28. Global Biologics Contract Manufacturing Revenue, (US$ Million), 2021 vs 2025 vs 2032 Figure 29. Global Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 30. Global Biologics Contract Manufacturing Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Figure 31. Global Biologics Contract Manufacturing Revenue-Based Market Share by Region (2021-2032) Figure 32. Global Biologics Contract Manufacturing Revenue-Based Market Share Ranking (2025) Figure 33. Tier Distribution by Revenue Contribution (2021 vs 2025) Figure 34. Monoclonal and Multispecific Antibodies Revenue-Based Market Share by Player in 2025 Figure 35. Antibody-Drug Conjugates (ADCs) Revenue-Based Market Share by Player in 2025 Figure 36. Vaccines Revenue-Based Market Share by Player in 2025 Figure 37. Cell Therapy Products Revenue-Based Market Share by Player in 2025 Figure 38. Gene Therapy and Viral Vector Products Revenue-Based Market Share by Player in 2025 Figure 39. Nucleic Acid Therapeutics Revenue-Based Market Share by Player in 2025 Figure 40. Others Revenue-Based Market Share by Player in 2025 Figure 41. Global Biologics Contract Manufacturing Revenue-Based Market Share by Type (2021-2032) Figure 42. Global Biologics Contract Manufacturing Revenue-Based Market Share by Manufacturing Service Type 按 (2021-2032) Figure 43. Global Biologics Contract Manufacturing Revenue-Based Market Share by Development and Commercialization Stage (2021-2032) Figure 44. Global Biologics Contract Manufacturing Revenue-Based Market Share by Application (2021-2032) Figure 45. North America Biologics Contract Manufacturing Revenue YoY (US$ Million), 2021-2032 Figure 46. North America Top 5 Players Biologics Contract Manufacturing Revenue (US$ Million) in 2025 Figure 47. North America Biologics Contract Manufacturing Revenue (US$ Million) by Application (2021-2032) Figure 48. US Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 49. Canada Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 50. Mexico Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 51. Europe Biologics Contract Manufacturing Revenue YoY (US$ Million), 2021-2032 Figure 52. Europe Top 5 Players Biologics Contract Manufacturing Revenue (US$ Million) in 2025 Figure 53. Europe Biologics Contract Manufacturing Revenue (US$ Million) by Application (2021-2032) Figure 54. Germany Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 55. France Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 56. U.K. Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 57. Italy Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 58. Russia Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 59. Asia-Pacific Biologics Contract Manufacturing Revenue YoY (US$ Million), 2021-2032 Figure 60. Asia-Pacific Top 8 Players Biologics Contract Manufacturing Revenue (US$ Million) in 2025 Figure 61. Asia-Pacific Biologics Contract Manufacturing Revenue (US$ Million) by Application (2021-2032) Figure 62. Indonesia Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 63. Japan Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 64. South Korea Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 65. Australia Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 66. India Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 67. Indonesia Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 68. Vietnam Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 69. Malaysia Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 70. Philippines Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 71. Singapore Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 72. Central and South America Biologics Contract Manufacturing Revenue YoY (US$ Million), 2021-2032 Figure 73. Central and South America Top 5 Players Biologics Contract Manufacturing Revenue (US$ Million) in 2025 Figure 74. Central and South America Biologics Contract Manufacturing Revenue (US$ Million) by Application (2021-2032) Figure 75. Brazil Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 76. Argentina Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 77. Middle East and Africa Biologics Contract Manufacturing Revenue YoY (US$ Million), 2021-2032 Figure 78. Middle East and Africa Top 5 Players Biologics Contract Manufacturing Revenue (US$ Million) in 2025 Figure 79. Middle East and Africa Biologics Contract Manufacturing Revenue (US$ Million) by Application (2021-2032) Figure 80. GCC Countries Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 81. Israel Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 82. Egypt Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 83. South Africa Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032 Figure 84. Biologics Contract Manufacturing Value Chain Mapping Figure 85. Channels of Distribution (Direct Vs Distribution) Figure 86. Bottom-up and Top-down Approaches for This Report Figure 87. Data Triangulation Figure 88. Key Executives Interviewed
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(ソフトウェア)の最新刊レポート
QYResearch社の サービス・ソフトウェア分野 での最新刊レポート本レポートと同じKEY WORD(biologics)の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|